The Experts below are selected from a list of 17199 Experts worldwide ranked by ideXlab platform
Chikara Ohyama - One of the best experts on this subject based on the ideXlab platform.
-
pd13 03 the impact of preoperative chronic kidney disease on oncological outcomes after trans urethral resection of Bladder tumor in patients with primary non muscle Invasive Bladder Cancer
The Journal of Urology, 2019Co-Authors: Naoki Fujita, Shingo Hatakeyama, Masaki Momota, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Atsushi Imai, Chikara OhyamaAbstract:INTRODUCTION AND OBJECTIVES:Previous studies reported preoperative renal insufficiency indicated poor prognosis in upper urinary tract carcinoma and muscle-Invasive Bladder Cancer (MIBC). However, ...
-
utility of robot assisted radical cystectomy with intracorporeal urinary diversion for muscle Invasive Bladder Cancer
International Journal of Urology, 2019Co-Authors: Takuya Koie, Chikara Ohyama, Kazuhide Makiyama, Toru Shimazui, Tomoaki Miyagawa, Kosuke Mizutani, Tomohiro Tsuchiya, Taku Kato, Keita NakaneAbstract:Radical cystectomy remains the gold standard for treatment of muscle-Invasive Bladder Cancer. Robot-assisted radical cystectomy has technical advantages over laparoscopic radical cystectomy and has emerged as an alternative to open radical cystectomy. Despite the advancements in robotic surgery, experience with total intracorporeal reconstruction of urinary diversion remains limited. Most surgeons have carried out the hybrid approach of robot-assisted radical cystectomy and extracorporeal reconstruction of urinary diversion, as intracorporeal reconstruction of urinary diversion remains technically challenging. However, intracorporeal reconstruction of urinary diversion might potentially proffer additional benefits, such as decreased fluid loss, reduction in estimated blood loss and a quicker return of bowel function. The adoption of intracorporeal ileal neoBladder reconstruction has hitherto been limited to high-volume academic institutions. In the present review, we compare the totally intracorporeal robot-assisted radical cystectomy approach with open radical cystectomy and robot-assisted radical cystectomy + extracorporeal reconstruction of urinary diversion in muscle-Invasive Bladder Cancer patients.
-
Utility of robot‐assisted radical cystectomy with intracorporeal urinary diversion for muscle‐Invasive Bladder Cancer
'Wiley', 2019Co-Authors: 島居 徹, Takuya Koie, Chikara Ohyama, Kazuhide Makiyama, Toru Shimazui, Tomoaki Miyagawa, Kosuke Mizutani, Tomohiro Tsuchiya, Taku Kato, Keita NakaneAbstract:Radical cystectomy remains the gold standard for treatment of muscle‐Invasive Bladder Cancer. Robot‐assisted radical cystectomy has technical advantages over laparoscopic radical cystectomy and has emerged as an alternative to open radical cystectomy. Despite the advancements in robotic surgery, experience with total intracorporeal reconstruction of urinary diversion remains limited. Most surgeons have carried out the hybrid approach of robot‐assisted radical cystectomy and extracorporeal reconstruction of urinary diversion, as intracorporeal reconstruction of urinary diversion remains technically challenging. However, intracorporeal reconstruction of urinary diversion might potentially proffer additional benefits, such as decreased fluid loss, reduction in estimated blood loss and a quicker return of bowel function. The adoption of intracorporeal ileal neoBladder reconstruction has hitherto been limited to high‐volume academic institutions. In the present review, we compare the totally intracorporeal robot‐assisted radical cystectomy approach with open radical cystectomy and robot‐assisted radical cystectomy + extracorporeal reconstruction of urinary diversion in muscle‐Invasive Bladder Cancer patients
-
renal function outcomes and risk factors for risk factors for stage 3b chronic kidney disease after urinary diversion in patients with muscle Invasive Bladder Cancer
PLOS ONE, 2016Co-Authors: Shingo Hatakeyama, Takuya Koie, Hayato Yamamoto, Takuma Narita, Shogo Hosogoe, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara OhyamaAbstract:The words “Risk Factors for” appear twice in the title of this article. The correct title is: Renal Function Outcomes and Risk Factors for Stage 3B Chronic Kidney Disease after Urinary Diversion in Patients with Muscle Invasive Bladder Cancer. The correct citation is: Hatakeyama S, Koie T, Narita T, Hosogoe S, Yamamoto H, Tobisawa Y, et al. (2016) Renal Function Outcomes and Risk Factors for Stage 3B Chronic Kidney Disease after Urinary Diversion in Patients with Muscle Invasive Bladder Cancer. PLoS ONE 11(2): e0149544. doi:10.1371/journal.pone.0149544
-
trans urethral whole layer core biopsy for detection of residual tumor after neoadjuvant therapy in Invasive Bladder Cancer
Urologic Oncology-seminars and Original Investigations, 2001Co-Authors: Senji Hoshi, Chikara Ohyama, Kenichi Suzuki, Takashige Namima, Seiichi OrikasaAbstract:Abstract The most essential information necessary for the treatment of Bladder Cancer is to know its exact staging. We have developed a percutaneous whole layer core biopsy (PC-WLCB) of the Bladder tumor and applied it successfully since April 1985 for the staging and evaluation of neoadjuvant therapy in locally Invasive Bladder Cancer. We report here a modified method, the trans-urethral WLCB (TU-WLCB) and present its clinical results. Methods: A 20 F. rigid nephroscope was introduced trans-urethrally and an 18 gauge, 350mm-long biopsy needle or newly developed 450mm-long biopsy needle was advanced to the tumor through the nephroscope. Biopsy was performed under trans-abdominal ultrasound guidance. Results: Specimens of all 20 TU-WLCB cases included the muscle layer and adipose tissue, and demonstrated small focus of residual Cancers after neoadjuvant therapy. Serious complications were not observed so far. Conclusion: TU-WLCB may prove to be a reliable method to stage and evaluate neoadjuvant therapy for Invasive Bladder Cancer.
Jian Huang - One of the best experts on this subject based on the ideXlab platform.
-
serum ccl27 predicts the response to bacillus calmette guerin immunotherapy in non muscle Invasive Bladder Cancer
OncoImmunology, 2020Co-Authors: Wenlong Zhong, Bo Wang, Jianxun Lin, Kun Xia, Weibin Hou, Meihua Yang, Junyu Chen, Meng Yang, Xiaofei Wang, Jian HuangAbstract:The prediction of the response to Bacillus Calmette-Guerin (BCG) can help identify non-muscle-Invasive Bladder Cancer (NMIBC) patients that may be better served with alternative therapy. Several cy...
-
diagnosis of narrow band imaging in non muscle Invasive Bladder Cancer a systematic review and meta analysis
International Journal of Urology, 2013Co-Authors: Kaiwen Li, Yu Duan, Jian HuangAbstract:Objectives The objective was to evaluate the diagnostic accuracy of cystoscopy assisted by narrow-band imaging compared with white-light imaging for non-muscle-Invasive Bladder Cancer. Methods An electronic database search of PubMed, Embase, the Cochrane Library, Ovid and Web of Science was carried out for all articles comparing narrow-band imaging with white-light imaging cystoscopy in the detection of non-muscle-Invasive Bladder Cancer. The review process followed the guidelines of the Cochrane Collaboration. Results Seven studies with prospectively collected data including a total of 1040 patients were identified, and 611 patients with 1476 tumors were detected by biopsy. In the patient- and tumor-level analysis, an additional 17% of patients (95% confidence interval, 10–25%) and an additional 24% of tumors (95% confidence interval, 17–31%) were detected by narrow-band imaging, respectively. In the patient- and tumor-level analysis, significantly higher detection rates using narrow-band imaging (rate difference 11%; 95% confidence interval 5–17%; P < 0.001; and rate difference 19%; 95% confidence interval 12–26%; P < 0.001, respectively) rather than white-light imaging were found. On the tumor level, an additional 28% of carcinoma in situ was detected (95% confidence interval 14–45%) by narrow-band imaging, and a significantly higher detection rate (rate difference 11%; 95% confidence interval 1–21%; P = 0.03) was found. The false-positive detection rate of tumor level did not differ significantly between the two techniques. Conclusions Cystoscopy assisted by narrow-band imaging detects more patients and tumors of non-muscle-Invasive Bladder Cancer than white-light imaging, and it might be an additional or alternative diagnostic technique for non-muscle-Invasive Bladder Cancer.
Takuya Koie - One of the best experts on this subject based on the ideXlab platform.
-
utility of robot assisted radical cystectomy with intracorporeal urinary diversion for muscle Invasive Bladder Cancer
International Journal of Urology, 2019Co-Authors: Takuya Koie, Chikara Ohyama, Kazuhide Makiyama, Toru Shimazui, Tomoaki Miyagawa, Kosuke Mizutani, Tomohiro Tsuchiya, Taku Kato, Keita NakaneAbstract:Radical cystectomy remains the gold standard for treatment of muscle-Invasive Bladder Cancer. Robot-assisted radical cystectomy has technical advantages over laparoscopic radical cystectomy and has emerged as an alternative to open radical cystectomy. Despite the advancements in robotic surgery, experience with total intracorporeal reconstruction of urinary diversion remains limited. Most surgeons have carried out the hybrid approach of robot-assisted radical cystectomy and extracorporeal reconstruction of urinary diversion, as intracorporeal reconstruction of urinary diversion remains technically challenging. However, intracorporeal reconstruction of urinary diversion might potentially proffer additional benefits, such as decreased fluid loss, reduction in estimated blood loss and a quicker return of bowel function. The adoption of intracorporeal ileal neoBladder reconstruction has hitherto been limited to high-volume academic institutions. In the present review, we compare the totally intracorporeal robot-assisted radical cystectomy approach with open radical cystectomy and robot-assisted radical cystectomy + extracorporeal reconstruction of urinary diversion in muscle-Invasive Bladder Cancer patients.
-
Utility of robot‐assisted radical cystectomy with intracorporeal urinary diversion for muscle‐Invasive Bladder Cancer
'Wiley', 2019Co-Authors: 島居 徹, Takuya Koie, Chikara Ohyama, Kazuhide Makiyama, Toru Shimazui, Tomoaki Miyagawa, Kosuke Mizutani, Tomohiro Tsuchiya, Taku Kato, Keita NakaneAbstract:Radical cystectomy remains the gold standard for treatment of muscle‐Invasive Bladder Cancer. Robot‐assisted radical cystectomy has technical advantages over laparoscopic radical cystectomy and has emerged as an alternative to open radical cystectomy. Despite the advancements in robotic surgery, experience with total intracorporeal reconstruction of urinary diversion remains limited. Most surgeons have carried out the hybrid approach of robot‐assisted radical cystectomy and extracorporeal reconstruction of urinary diversion, as intracorporeal reconstruction of urinary diversion remains technically challenging. However, intracorporeal reconstruction of urinary diversion might potentially proffer additional benefits, such as decreased fluid loss, reduction in estimated blood loss and a quicker return of bowel function. The adoption of intracorporeal ileal neoBladder reconstruction has hitherto been limited to high‐volume academic institutions. In the present review, we compare the totally intracorporeal robot‐assisted radical cystectomy approach with open radical cystectomy and robot‐assisted radical cystectomy + extracorporeal reconstruction of urinary diversion in muscle‐Invasive Bladder Cancer patients
-
renal function outcomes and risk factors for risk factors for stage 3b chronic kidney disease after urinary diversion in patients with muscle Invasive Bladder Cancer
PLOS ONE, 2016Co-Authors: Shingo Hatakeyama, Takuya Koie, Hayato Yamamoto, Takuma Narita, Shogo Hosogoe, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara OhyamaAbstract:The words “Risk Factors for” appear twice in the title of this article. The correct title is: Renal Function Outcomes and Risk Factors for Stage 3B Chronic Kidney Disease after Urinary Diversion in Patients with Muscle Invasive Bladder Cancer. The correct citation is: Hatakeyama S, Koie T, Narita T, Hosogoe S, Yamamoto H, Tobisawa Y, et al. (2016) Renal Function Outcomes and Risk Factors for Stage 3B Chronic Kidney Disease after Urinary Diversion in Patients with Muscle Invasive Bladder Cancer. PLoS ONE 11(2): e0149544. doi:10.1371/journal.pone.0149544
Keita Nakane - One of the best experts on this subject based on the ideXlab platform.
-
utility of robot assisted radical cystectomy with intracorporeal urinary diversion for muscle Invasive Bladder Cancer
International Journal of Urology, 2019Co-Authors: Takuya Koie, Chikara Ohyama, Kazuhide Makiyama, Toru Shimazui, Tomoaki Miyagawa, Kosuke Mizutani, Tomohiro Tsuchiya, Taku Kato, Keita NakaneAbstract:Radical cystectomy remains the gold standard for treatment of muscle-Invasive Bladder Cancer. Robot-assisted radical cystectomy has technical advantages over laparoscopic radical cystectomy and has emerged as an alternative to open radical cystectomy. Despite the advancements in robotic surgery, experience with total intracorporeal reconstruction of urinary diversion remains limited. Most surgeons have carried out the hybrid approach of robot-assisted radical cystectomy and extracorporeal reconstruction of urinary diversion, as intracorporeal reconstruction of urinary diversion remains technically challenging. However, intracorporeal reconstruction of urinary diversion might potentially proffer additional benefits, such as decreased fluid loss, reduction in estimated blood loss and a quicker return of bowel function. The adoption of intracorporeal ileal neoBladder reconstruction has hitherto been limited to high-volume academic institutions. In the present review, we compare the totally intracorporeal robot-assisted radical cystectomy approach with open radical cystectomy and robot-assisted radical cystectomy + extracorporeal reconstruction of urinary diversion in muscle-Invasive Bladder Cancer patients.
-
Utility of robot‐assisted radical cystectomy with intracorporeal urinary diversion for muscle‐Invasive Bladder Cancer
'Wiley', 2019Co-Authors: 島居 徹, Takuya Koie, Chikara Ohyama, Kazuhide Makiyama, Toru Shimazui, Tomoaki Miyagawa, Kosuke Mizutani, Tomohiro Tsuchiya, Taku Kato, Keita NakaneAbstract:Radical cystectomy remains the gold standard for treatment of muscle‐Invasive Bladder Cancer. Robot‐assisted radical cystectomy has technical advantages over laparoscopic radical cystectomy and has emerged as an alternative to open radical cystectomy. Despite the advancements in robotic surgery, experience with total intracorporeal reconstruction of urinary diversion remains limited. Most surgeons have carried out the hybrid approach of robot‐assisted radical cystectomy and extracorporeal reconstruction of urinary diversion, as intracorporeal reconstruction of urinary diversion remains technically challenging. However, intracorporeal reconstruction of urinary diversion might potentially proffer additional benefits, such as decreased fluid loss, reduction in estimated blood loss and a quicker return of bowel function. The adoption of intracorporeal ileal neoBladder reconstruction has hitherto been limited to high‐volume academic institutions. In the present review, we compare the totally intracorporeal robot‐assisted radical cystectomy approach with open radical cystectomy and robot‐assisted radical cystectomy + extracorporeal reconstruction of urinary diversion in muscle‐Invasive Bladder Cancer patients
Kent W Mouw - One of the best experts on this subject based on the ideXlab platform.
-
mutational patterns in chemotherapy resistant muscle Invasive Bladder Cancer
Nature Communications, 2017Co-Authors: David Liu, Philip Abbosh, Daniel Keliher, Brendan Reardon, Diana Miao, Kent W MouwAbstract:Despite continued widespread use, the genomic effects of cisplatin-based chemotherapy and implications for subsequent treatment are incompletely characterized. Here, we analyze whole exome sequencing of matched pre- and post-neoadjuvant cisplatin-based chemotherapy primary Bladder tumor samples from 30 muscle-Invasive Bladder Cancer patients. We observe no overall increase in tumor mutational burden post-chemotherapy, though a significant proportion of subclonal mutations are unique to the matched pre- or post-treatment tumor, suggesting chemotherapy-induced and/or spatial heterogeneity. We subsequently identify and validate a novel mutational signature in post-treatment tumors consistent with known characteristics of cisplatin damage and repair. We find that post-treatment tumor heterogeneity predicts worse overall survival, and further observe alterations in cell-cycle and immune checkpoint regulation genes in post-treatment tumors. These results provide insight into the clinical and genomic dynamics of tumor evolution with cisplatin-based chemotherapy, suggest mechanisms of clinical resistance, and inform development of clinically relevant biomarkers and trials of combination therapies. The impact of cisplatin-based chemotherapy on tumor genomes is complex. Here, the authors study matched pre- and post-chemotherapy primary samples in muscle-Invasive Bladder Cancer, finding a cisplatin-based mutational signature, and highlighting the impact of intratumor heterogeneity on survival.
-
mutational patterns in chemotherapy resistant muscle Invasive Bladder Cancer
Nature Communications, 2017Co-Authors: Philip Abbosh, Daniel Keliher, Brendan Reardon, Diana Miao, David R Liu, Kent W MouwAbstract:Despite continued widespread use, the genomic effects of cisplatin-based chemotherapy and implications for subsequent treatment are incompletely characterized. Here, we analyze whole exome sequencing of matched pre- and post-neoadjuvant cisplatin-based chemotherapy primary Bladder tumor samples from 30 muscle-Invasive Bladder Cancer patients. We observe no overall increase in tumor mutational burden post-chemotherapy, though a significant proportion of subclonal mutations are unique to the matched pre- or post-treatment tumor, suggesting chemotherapy-induced and/or spatial heterogeneity. We subsequently identify and validate a novel mutational signature in post-treatment tumors consistent with known characteristics of cisplatin damage and repair. We find that post-treatment tumor heterogeneity predicts worse overall survival, and further observe alterations in cell-cycle and immune checkpoint regulation genes in post-treatment tumors. These results provide insight into the clinical and genomic dynamics of tumor evolution with cisplatin-based chemotherapy, suggest mechanisms of clinical resistance, and inform development of clinically relevant biomarkers and trials of combination therapies.
